Audax acquires Altasciences from Kilmer and BMO Capital Parners

Photo of author

By Ted Liu

Audax Private Equity has acquired Altasciences Company Inc., a leading early phase contract research organization (CRO) in North America, from Kilmer Capital Partners and BMO Capital Partners. Financial terms were not disclosed.

Laval, Quebec based Altasciences, operating through Algorithme Pharma, Vince & Associates Clinical Research, and Algorithme Pharma USA, offers expertise in the execution of a wide range of New Drug Application (NDA) enabling clinical trials and support services including data management, biostatistics, medical writing, and bioanalysis.

Kilmer Capital Fund II and BMO Capital Partners acquired Algorithme Pharma in September 2007. Altasciences acquired Overland Park, Kansas based Vince & Associates Clinical Research in May 2013.

“Altasciences is a leader in the early phase clinical research industry. We look forward to working with Chris Perkin and the Altasciences team to continue building a leading platform through organic growth and add-on acquisitions,” said Geoffrey S. Rehnert, co-CEO of Audax Group.

“We are excited to be partnering with Audax for the next stage of our growth. Audax brings expertise and resources that will help us continue to build our market leadership position by expanding our service offering and value proposition to our clients through strategic acquisitions and growth initiatives,” said Chris Perkin, CEO of Altasciences.

Fairmount Partners served as financial advisor to Altasciences. Blake, Cassels & Graydon, LLP and Kirkland & Ellis, LLP served as counsel to Audax.

photo credit: Altasciences